The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib.
The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib.
复制标题
阿帕替尼治疗转移性胃癌外周血基线血液学参数的预后价值
DOI：
10.7150/jca.65339
复制
发表时间：
2022
影响因子：
3.9
通讯作者：
Yu DD
中科院分区：
文献类型：
--
作者：
Yang JR;Zhou DY;Wu Y;Zhu Y;Lin ZY;Zhang T;Yu DD
背景：有强有力的证据表明阿帕替尼可有效治疗三线或三线以上晚期转移性胃癌（mGC）。血液学预测指标是一种简便、廉价的预测疾病预后的方法。然而，尚未确定外周血基线血液学参数（如嗜中性粒细胞/淋巴细胞比值（NLR）、碳水化合物抗原125（CA 125）和白蛋白（ALB））对阿帕替尼治疗mGC的预后。方法：我们回顾性分析了2014年1月1日至2021年6月30日期间接受阿帕替尼治疗的mGC。使用Kaplan-Meier方法和Cox比例风险模型进行生存分析。结果：共有117例患者纳入本研究。NLR、CA 125和ALB的临界值分别为2.25、19.24 U/ml和37.60 g/L。高、低NLR组疾病控制率分别为52.94%和73.47%（P=0.024），高、低CA 125组分别为48.28%和74.58%（P=0.003），高、低ALB组分别为72.97%和41.86%（P=0.001）。通过生存分析，增加NLR（P=0.003），CA 125（P<0.001）和降低ALB（P<0.001）预测阿帕替尼治疗后PFS较短。NLR（P=0.015）、CA 125（P=0.004）和ALB（P=0.005）是aptinib治疗mGC的PFS的显著预测因素。结论：阿帕替尼治疗后NLR、CA 125升高和ALB降低与临床疗效和预后不良相关。
Background: There is strong evidence that apatinib is effective in the treatment of third- or later-line advanced metastatic gastric cancer (mGC). Hematology prediction index is a convenient and cheap method to predict the prognosis of disease. However, the prognosis of baseline hematological parameters of peripheral blood, such as neutrophil-to-lymphocyte ratio (NLR), carbohydrate antigen 125 (CA125) and albumin (ALB) on mGC treated with apatinib have not been identified. Methods: We retrospectively analyzed mGC received apatinib between 1 January 2014 and 30 June 2021. Survival analyses were performed using the Kaplan-Meier method and Cox-proportional hazards model. Results: A total of 117 patients were included in this study. The cutoff value of NLR, CA125 and ALB was 2.25, 19.24 U/ml and 37.60 g/L, respectively. The disease control rates (DCR) in the high and low NLR groups were 52.94% and 73.47% (P=0.024); 48.28% and 74.58% (P=0.003) in high and low CA125 groups; 72.97% and 41.86% (P=0.001) in high and low ALB groups. By survival analysis, increasing NLR (P=0.003), CA125 (P<0.001) and decreasing ALB (P<0.001) predicted a shorter PFS after apatinib. NLR (P=0.015), CA125 (P=0.004) and ALB (P=0.005) were significantly predictors for PFS in mGC treated with aptinib. Conclusion: Increasing NLR, CA125 and decreasing ALB were associated with poorer clinical efficiency and prognosis after apatinib treatment.